Literature DB >> 24947794

Health-related quality of life in Korean lymphoma survivors compared with the general population.

Soo Hyun Kim1, Im-Ryung Kim, So Hee Kim, Suyeon Lee, Onam Ok, Won Seog Kim, Cheolwon Suh, Moon Hee Lee.   

Abstract

The objective of this study was to evaluate the health-related quality of life (HRQOL) of lymphoma survivors, to compare it with that of the general population, and to identify its predictors in lymphoma survivors. We enrolled 837 participants (mean age, 54.6 years; mean time since diagnosis, 6.3 years) with a history of Hodgkin's lymphoma (HL) (n = 58) or non-Hodgkin's lymphoma (NHL) (n = 779) who had been treated at any of three Korean hospitals from 1989 through 2010. For controls, we selected 1,000 subjects randomly from a representative Korean population. We administered the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the Hospital Anxiety and Depression Scale. Overall, the HRQOL in both groups of survivors and the general population were comparable, but we observed clinically meaningful worse social functioning in NHL survivors (p < 0.001) and more severe fatigue in HL survivors (p < 0.001) than in the general population. Analysis of covariance revealed no clinically meaningful difference in HRQOL associated with age or sex. Survivors who received peripheral blood stem cell transplants showed clinically meaningful worse role (p = 0.001) and social (p < 0.001) functioning than those who were treated with first-line chemotherapy alone. In multivariate analyses, fatigue, depression, and financial difficulties emerged as the strongest predictors for almost all subscales of functioning and global quality of life. Interventions for alleviating fatigue, depression, and financial difficulties are needed to enhance the HRQOL of Korean lymphoma survivors.

Entities:  

Mesh:

Year:  2014        PMID: 24947794     DOI: 10.1007/s00277-014-2091-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

Review 1.  High dose therapy and autologous hematopoietic stem cell transplantation in septuagenarians with non-Hodgkin lymphoma: Feasible, but for which patients?

Authors:  Tanya M Wildes; Amanda Cashen
Journal:  J Geriatr Oncol       Date:  2015-08-10       Impact factor: 3.599

2.  Exploring health-related quality of life among non-Hodgkin's lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand.

Authors:  Pichitra Lekdamrongkul; Kanaungnit Pongthavornkamol; Alex Molassiotis; Aurawamon Sriyuktasuth; Noppadol Siritanaratkul; Natkamol Chansatitporn
Journal:  Support Care Cancer       Date:  2021-04-28       Impact factor: 3.603

3.  Financial toxicity in hematological malignancies: a systematic review.

Authors:  Evguenia Ouchveridze; Rahul Banerjee; Aakash Desai; Muhammad Aziz; Wade Lee-Smith; Hira Mian; Katherine Berger; Brian McClune; Douglas Sborov; Muzaffar Qazilbash; Shaji Kumar; Ghulam Rehman Mohyuddin
Journal:  Blood Cancer J       Date:  2022-04-22       Impact factor: 9.812

Review 4.  Health-related quality of life in Hodgkin lymphoma: a systematic review.

Authors:  Nadine Linendoll; Tully Saunders; Rebecca Burns; Jonathan D Nyce; Kristen B Wendell; Andrew M Evens; Susan K Parsons
Journal:  Health Qual Life Outcomes       Date:  2016-07-29       Impact factor: 3.186

5.  Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study.

Authors:  Danbee Kang; Juhee Cho; Im Ryung Kim; Mi Kyung Kim; Won Seog Kim; Seok Jin Kim
Journal:  Cancer Res Treat       Date:  2017-11-09       Impact factor: 4.679

6.  Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors.

Authors:  Vanessa Boland; Amanda Drury; Greg Sheaf; Anne-Marie Brady
Journal:  Psychooncology       Date:  2022-06-27       Impact factor: 3.955

7.  Impact of health-related stigma on psychosocial functioning in cancer patients: Construct validity of the stigma-related social problems scale.

Authors:  Emma Ohlsson-Nevo; Johan Ahlgren; Jan Karlsson
Journal:  Eur J Cancer Care (Engl)       Date:  2020-08-31       Impact factor: 2.520

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.